Hidradenitis suppurativa trials in China

In China 13 Also abroad 72

10 of 13 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Where
Beijing
Age
18 years to 100 years
People
710 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07665437 · EU 2025-523259-72-00
Phase 2Taking people
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Where
Beijing, Changsha, Hangzhou, Shanghai, Wuhan
Age
18 years and over
People
144 worldwide
Run by
Sanofi
See details and how to joinNCT07225569 · EU 2025-522695-83-00
Phase 2Taking people
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Where
Chengdu, Guangzhou, Shanghai, Ürümqi
Age
18 years and over
People
208 worldwide
Run by
Sanofi
See details and how to joinNCT07170917 · EU 2025-522333-61-00
Phase 4Taking people
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Ningbo, Shanghai, Shijiazhuang, Tianjin, Wenzhou
Age
18 years and over
People
36
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07489573
Phase 1/2Taking people
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa
Where
Beijing
Age
18 years to 75 years
People
12
Run by
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
See details and how to joinNCT06932003
Phase 4Not yet taking people in China
A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A/F Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa
Where
Hangzhou
Age
18 years and over
People
50
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07554014
Phase 1/2Taking people
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
Where
Jinan
Age
18 years and over
People
15
Run by
Shanghai Huaota Biopharmaceutical Co., Ltd.
See details and how to joinNCT06895499
Phase 4Not yet taking people in China
Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS
Where
Nanjing
Age
18 years and over
People
30
Run by
Peking Union Medical College
See details and how to joinNCT07261072
Phase 1Taking people
A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
Where
Beijing
Age
18 years to 75 years
People
102
Run by
Shanghai Qilu Pharmaceutical Research and Development Center LTD
See details and how to joinNCT06946641
No phaseTaking people
A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Suppurativa in Chinese Patients
Where
Hangzhou
Age
18 years to 75 years
People
60
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06707246